MX371158B - Compuestos inhibidores de pde2. - Google Patents

Compuestos inhibidores de pde2.

Info

Publication number
MX371158B
MX371158B MX2017007380A MX2017007380A MX371158B MX 371158 B MX371158 B MX 371158B MX 2017007380 A MX2017007380 A MX 2017007380A MX 2017007380 A MX2017007380 A MX 2017007380A MX 371158 B MX371158 B MX 371158B
Authority
MX
Mexico
Prior art keywords
organic compounds
pharmaceuticals
formula
pharmaceutical compositions
relates
Prior art date
Application number
MX2017007380A
Other languages
English (en)
Spanish (es)
Other versions
MX2017007380A (es
Inventor
P Wennogle Lawrence
Li Peng
Zheng Hailin
Snyder Gretchen
Hendrick Joseph
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of MX2017007380A publication Critical patent/MX2017007380A/es
Publication of MX371158B publication Critical patent/MX371158B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2017007380A 2014-12-06 2015-12-07 Compuestos inhibidores de pde2. MX371158B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462088541P 2014-12-06 2014-12-06
PCT/US2015/064324 WO2016090380A1 (en) 2014-12-06 2015-12-07 Organic compounds

Publications (2)

Publication Number Publication Date
MX2017007380A MX2017007380A (es) 2017-10-20
MX371158B true MX371158B (es) 2020-01-20

Family

ID=56092607

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007380A MX371158B (es) 2014-12-06 2015-12-07 Compuestos inhibidores de pde2.

Country Status (13)

Country Link
US (1) US10300064B2 (enExample)
EP (1) EP3226870B1 (enExample)
JP (1) JP6608934B2 (enExample)
KR (1) KR102557603B1 (enExample)
CN (1) CN107205999B (enExample)
AU (1) AU2015357496B2 (enExample)
BR (1) BR112017012007B1 (enExample)
CA (1) CA2969594A1 (enExample)
HK (1) HK1243936A1 (enExample)
IL (1) IL252579B (enExample)
MX (1) MX371158B (enExample)
RU (1) RU2709786C2 (enExample)
WO (1) WO2016090380A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291666B2 (en) 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
MX2020011275A (es) 2018-04-25 2020-11-13 Bayer Ag Novedosos compuestos de heteroaril-triazol y hetroaril[-]tetrazol como plaguicidas.
EP3870300B1 (en) * 2018-10-23 2024-07-10 Intra-Cellular Therapies, Inc. Imidazo[1,5-a]pyrazine compounds as pde2 inhibitors
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603203A (en) 1983-12-14 1986-07-29 Takeda Chemical Industries, Ltd. 3-aminopyrazolo[3,4-d]pyrimidine derivatives and production thereof
CA1251448A (en) 1985-03-27 1989-03-21 William J. Coates Pyridazinone derivatives
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
ATE126207T1 (de) 1989-01-26 1995-08-15 Bayer Ag Optisch aktive (meth)acrylsäure-derivate, ihre herstellung, ihre polymerisation zu optisch aktiven polymeren und deren verwendung.
IL98559A0 (en) 1990-06-21 1992-07-15 Schering Corp Polycyclic guanine derivatives
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
JPH08507068A (ja) 1993-02-26 1996-07-30 シェリング・コーポレーション ２−ベンジル−多環式グアニン誘導体およびそれらの製造方法
DE19541264A1 (de) 1995-11-06 1997-05-07 Bayer Ag Purin-6-on-derivate
US5824683A (en) 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
DE19702785A1 (de) 1997-01-27 1998-07-30 Bayer Ag Neue cyclische Harnstoffderivate
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US6013621A (en) 1997-10-17 2000-01-11 The Rockfeller University Method of treating psychosis and/or hyperactivity
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
DE19931206A1 (de) 1999-07-07 2001-01-11 Stief Christian Arzneimittel zur Erhöhung des cAMP-Spiegels und deren Verwendung
AU7547900A (en) 1999-10-11 2001-04-23 Pfizer Inc. 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo(4,3-d)pyrimidin-7-ones as phosphodiesterase inhibitors
IL139073A0 (en) 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
CN1436080A (zh) 2000-04-19 2003-08-13 利利艾科斯有限公司 环gmp－特异性磷酸二酯酶抑制剂治疗帕金森氏病的用途
AU2001289751A1 (en) 2000-08-01 2002-02-13 Bayer Aktiengesellschaft Selective pde 2 inhibitors, used as medicaments for improving cognition
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
DE10108752A1 (de) 2001-02-23 2002-09-05 Bayer Ag Neue Substituierte Imidazotriazinone
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
JP4450365B2 (ja) 2001-08-28 2010-04-14 シェーリング コーポレイション 多環式グアニンホスホジエステラーゼｖ阻害剤
AU2002324846B2 (en) 2001-08-31 2007-05-10 Childrens Hospital Medical Center Phosphodiesterase activity and regulation of phosphodiesterase 1-B-mediated signaling in brain
CN1585771A (zh) 2001-11-09 2005-02-23 先灵公司 多环鸟嘌呤衍生物磷酸二酯酶v抑制剂
EP1476200A4 (en) 2002-02-21 2008-08-13 Univ Rockefeller COMPOSITION AND METHOD FOR REGULATING CALCIUM DEPENDENT SIGNALING IN THE BRAIN
WO2004041258A2 (fr) 2002-10-30 2004-05-21 Neuro3D Utilisation d’inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique en therapie
CN100572381C (zh) 2002-11-06 2009-12-23 Aska制药株式会社 吡唑并二氮杂萘衍生物
CA2517336A1 (en) 2003-03-04 2004-10-21 Altana Pharma Ag Purin-6-one-derivatives
WO2004087906A1 (en) 2003-03-31 2004-10-14 Pfizer Products Inc. Crystal structure of 3',5'-cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof
JP2006522151A (ja) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
WO2005041957A1 (en) 2003-10-29 2005-05-12 Pfizer Products Inc. Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors
PL1697356T3 (pl) 2003-12-16 2008-07-31 Pfizer Products Incorporated Pirydo[2,3-d]pirymidyno-2,4-diaminy jako inhibitory PDE 2
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
WO2005083069A1 (en) * 2004-01-30 2005-09-09 Pfizer Products Inc. Pde2 crystal structures for structure based drug design
DE602005021894D1 (de) 2004-09-02 2010-07-29 Nycomed Gmbh Triazolophthalazine
BRPI0606379A2 (pt) 2005-01-05 2009-06-23 Nycomed Gmbh triazolftalazinas
EP1874775B1 (en) 2005-01-05 2012-10-10 Nycomed GmbH Triazolophthalazines as pde2-inhibitors
DOP2006000009A (es) * 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
BRPI0611095B8 (pt) 2005-06-06 2021-05-25 Intracellular Therapies Inc compostos inibidores de pde1, composição farmacêutica compreendendo-os, usos dos mesmos como inibidores de pde1 para o tratamento de doenças relacionadas, tal como doença de parkinson e deficiência cognitiva, e métodos para produção dos ditos compostos
EP1749824A1 (en) 2005-08-03 2007-02-07 Neuro3D Benzodiazepine derivatives, their preparation and the therapeutic use thereof
WO2007025103A2 (en) 2005-08-23 2007-03-01 Intra-Cellular Therapies, Inc. Organic compounds for treating reduced dopamine receptor signalling activity
JP5060957B2 (ja) 2005-09-15 2012-10-31 あすか製薬株式会社 複素環化合物、その製造方法並びに用途
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
JP5453086B2 (ja) 2006-06-06 2014-03-26 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
ES2411604T3 (es) 2006-11-13 2013-07-05 Intra-Cellular Therapies, Inc. Compuestos orgánicos
US9006258B2 (en) 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
DK2152712T3 (da) 2007-05-11 2012-03-26 Pfizer Aminoheterocykliske fobindelser
US7807629B1 (en) 2007-06-05 2010-10-05 Alcon Research, Ltd. Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma
KR20120012831A (ko) 2007-12-06 2012-02-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
AU2008331833A1 (en) 2007-12-06 2009-06-11 Intra-Cellular Therapies, Inc Organic compounds
US20120065165A1 (en) 2008-10-31 2012-03-15 Arginetix, Inc Compositions and methods of treating endothelial disorders
US20100120763A1 (en) 2008-11-07 2010-05-13 Wyeth Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases
WO2010054253A1 (en) 2008-11-07 2010-05-14 Biotie Therapies Gmbh Triazine derivatives as inhibitors of phosphodiesterases
US8927556B2 (en) 2008-12-06 2015-01-06 Intra-Cellular Therapies, Inc. 1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds
EA201170769A1 (ru) 2008-12-06 2012-02-28 Интра-Селлулар Терапиз, Инк. Органические соединения
KR20110098731A (ko) 2008-12-06 2011-09-01 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
AU2009322901A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
WO2010065151A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
GEP20146029B (en) 2008-12-06 2014-02-10 Intracellular Therapies Inc Organic compounds
JP2012518685A (ja) 2009-02-25 2012-08-16 イントラ−セルラー・セラピーズ・インコーポレイテッド 眼障害のためのｐｄｅ１阻害剤
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
EP2456440B1 (en) 2009-07-22 2015-08-19 Merck Sharp & Dohme Corp. Quinolinone pde2 inhibitors
JP2013507360A (ja) 2009-10-08 2013-03-04 イントラ−セルラー・セラピーズ・インコーポレイテッド ホスホジエステラーゼ１−標的トレーサーおよび方法
EP2490693A4 (en) 2009-10-19 2013-02-27 Merck Sharp & Dohme Pyrazolo [3,4-B] PYRIDINE-4-ON-KINASE INHIBITORS
EP2575817A4 (en) 2010-05-31 2014-01-08 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
JP5894148B2 (ja) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
EP2576551A4 (en) 2010-05-31 2014-04-16 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
SG192576A1 (en) 2011-02-23 2013-09-30 Pfizer IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
KR101626681B1 (ko) * 2011-06-07 2016-06-01 화이자 인코포레이티드 피라졸로[3,4-d]피리미딘 화합물 및 pde2 억제제 및/또는 cyp3a4 억제제로서의 이의 용도
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP6115962B2 (ja) 2011-06-27 2017-04-19 ヤンセン ファーマシューティカ エヌ．ベー． １−アリール−４−メチル−［１，２，４］トリアゾロ［４，３−ａ］キノキサリン誘導体
WO2013034755A1 (en) 2011-09-09 2013-03-14 H. Lundbeck A/S Triazolopyrazine derivatives and their use for treating neurological and psychiatric disorders
WO2013034758A1 (en) 2011-09-09 2013-03-14 H. Lundbeck A/S Substituted triazolopyrazines and uses thereof
US9056863B2 (en) 2011-09-09 2015-06-16 H. Lundbeck A/S Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof
AR091507A1 (es) 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
DK2970279T3 (da) 2013-03-15 2020-11-30 Intra Cellular Therapies Inc Organiske forbindelser
KR20150135406A (ko) 2013-03-25 2015-12-02 사노피 Metap2(메티오닌 아미노펩티다아제 타입 2) 억제제로서의 피라졸로나프티리디논 유도체들
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds

Also Published As

Publication number Publication date
MX2017007380A (es) 2017-10-20
BR112017012007B1 (pt) 2022-11-01
RU2017123686A3 (enExample) 2019-07-17
KR20170089000A (ko) 2017-08-02
IL252579A0 (en) 2017-07-31
RU2709786C2 (ru) 2019-12-20
JP2017536410A (ja) 2017-12-07
KR102557603B1 (ko) 2023-07-19
RU2017123686A (ru) 2019-01-09
CN107205999B (zh) 2021-08-03
IL252579B (en) 2021-05-31
EP3226870B1 (en) 2019-09-25
US10300064B2 (en) 2019-05-28
EP3226870A1 (en) 2017-10-11
JP6608934B2 (ja) 2019-11-20
HK1243936A1 (zh) 2018-07-27
EP3226870A4 (en) 2018-05-30
US20170360792A1 (en) 2017-12-21
BR112017012007A2 (pt) 2017-12-26
CN107205999A (zh) 2017-09-26
WO2016090380A1 (en) 2016-06-09
CA2969594A1 (en) 2016-06-09
AU2015357496A1 (en) 2017-07-27
HK1243933A1 (zh) 2018-07-27
AU2015357496B2 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
MX373320B (es) Compuestos inhibidores de pde2.
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
TW201613911A (en) Heterocyclic compounds and uses thereof
MX378194B (es) Compuestos organicos.
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
PH12017502255B1 (en) Nrf2 regulators
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
MX2017008444A (es) Picolinamidas como fungicidas.
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
MX378732B (es) Formas solidas novedosas
MX2018015125A (es) Nuevos compuestos antibacterianos.
HK1245257A1 (zh) 具有广谱活性的抗菌化合物
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
EA033460B1 (ru) Замещенные [1,2,4]триазольные соединения в качестве фунгицидов
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12016501613B1 (en) Pyrazines modulators of gpr6
MX371158B (es) Compuestos inhibidores de pde2.
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs

Legal Events

Date Code Title Description
FG Grant or registration